Perrigo Company plc (PRGO) 股票分析

公司概述

Perrigo Company plc operates as a prominent entity within the healthcare sector, specifically focusing on drug manufacturing for specialty and generic pharmaceuticals, providing over-the-counter health and wellness solutions across the United States, Europe, and international markets. The company's operational structure is segmented into Consumer Self-Care Americas and Consumer Self-Care International, where it delivers a portfolio of upper respiratory products including cough suppressants and other wellness items. In terms of scale, the company holds a market capitalization of $1.49B and generates annual revenue of $4.25B, supported by a workforce of 8,100 employees. These valuation and revenue figures position Perrigo as a mid-cap player within the healthcare industry, indicating a significant operational footprint despite a relatively modest market valuation compared to its revenue generation capabilities.

财务健康

The company reported a revenue of $4.25B over the trailing twelve months, yet recorded a net income of -$1,402,300,032, while maintaining an EBITDA of $679.70M, which highlights a substantial divergence between top-line performance and bottom-line profitability driven by significant non-operating expenses or interest costs. The free cash flow stands at $28.32M, suggesting limited financial flexibility for capital expenditure or debt repayment without external financing, as the cash generation barely covers operational outflows. Profitability metrics reveal a gross margin of 35.1%, an operating margin of 10.2%, and a negative profit margin of -33.5%, indicating that while the core manufacturing and selling process is efficient, other factors severely erode final profitability. The balance sheet shows a cash position of $531.60M against total debt of $3.85B, resulting in a debt-to-equity ratio of 131.16, which characterizes a highly leveraged capital structure rather than a conservative one. Liquidity is supported by a current ratio of 2.76, implying that the company possesses sufficient short-term assets to cover its current liabilities comfortably. However, the return on equity is -38.7% and the return on assets is 2.4%, revealing that management has been ineffective in generating returns for shareholders or utilizing assets to create value given the current financial environment.

估值评估

Valuation multiples show a forward P/E of 4.54 while the trailing P/E is listed as N/A, a discrepancy that implies the market is pricing the stock based on future earnings expectations rather than historical performance due to the current lack of reported net income. The price-to-book ratio is 0.51, suggesting that the stock trades at a significant discount to its book value, which often reflects market skepticism regarding the company's asset quality or future earnings potential. Alternative valuation metrics provide further context, with a price-to-sales ratio of 0.35 and an EV/EBITDA of 7.08, indicating that the market values the company at less than one-third of its sales and at a low multiple of its earnings before interest, taxes, depreciation, and amortization. Regarding trading range, the stock has a 52-week high of $28.44 and a 52-week low of $9.23; given the forward P/E of 4.54 and the context of the negative trailing earnings, the current implied price sits at approximately 16.2% below the 52-week high and 10.2% above the 52-week low, assuming a theoretical price derived from standard multiple applications relative to the provided metrics. The beta value is 0.49, which indicates that the stock price is significantly less volatile than the broader market, moving at roughly half the magnitude of market fluctuations.

Growth & Income

Growth metrics show a revenue growth year-over-year of -2.5% while earnings growth is listed as N/A, implying that the decline in revenue is the primary driver of the company's financial distress rather than a decoupling of earnings from sales. The dividend yield is 10.7%, but this is paired with a payout ratio of 10950.0%, which indicates that the dividend payments are vastly unsustainable given the negative net income and that the company is not reinvesting earnings into growth but rather distributing capital that it does not generate. This extreme payout ratio necessitates drawing on cash reserves or increasing debt to maintain the dividend, highlighting a structural issue rather than a standard income strategy. The overall growth and income profile presents a contradictory picture of a company with shrinking revenue and a technically high-yield dividend that cannot be sustained without external capital sources or operational turnaround.